Rigel Pharma (RIGL) Reports In-Line Q1 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. NXPI
4. BA
5. STX
6. SPY
7. V
8. CSGP
9. LSTR
10. UPS

Go back to Rigel Pharma (RIGL) Reports In-Line Q1 Loss

Rigel Announces First Quarter 2016 Financial Results

May 3, 2016 4:06 PM EDT

SOUTH SAN FRANCISCO, Calif., May 3, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2016.

"We look forward to our upcoming Phase 3 data as we continue with our planning for the potential commercial launch of fostamatinib in the United States," said Raul Rodriguez, president and chief executive officer of Rigel.  "Also, we initiated the Phase 2 proof-of-concept study with fostamatinib in autoimmune hemolytic anemia (AIHA). We anticipate that the results of these studies as well as the IgA nephropathy study will be forthcoming... More